The Cost of Alzheimer Drug Treatment

Article Sidebar

PDF
Published Feb 17, 2026
DOI: https://doi.org/10.18103/mra.v14i1.7163

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Helmy M. Guirgis, MD, PhD
University of California, Irvine

Abstract

Introduction: The anti-amyloid drug donanemab is approved In the United States and Europe for treatment of early symptomatic Alzheimer’s disease (mild dementia) in adults with confirmed amyloid pathology. Evolocumab was also reported to lower the risks of heart attacks and Alzheimer. In view of longevity and continued early Alzheimer recognition, we planned to compare costs of donanemab and evolocumab with other drug classes.


Methods: Drug costs were obtained from Google search and yearly cost calculated.


Results: Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. Pembrolizumab was $160,00, durvalumab $115,000, Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000.


Conclusions: Donanemab $32,000 yearly cost was higher than evolocumab at $6,840. Both drugs were reasonably priced as compared with other classes. Considering longevity, the overall worldwide Alzheimer future management would be too costly to be affordable.

Article Details

How to Cite
GUIRGIS, Helmy M.. The Cost of Alzheimer Drug Treatment. Medical Research Archives, [S.l.], v. 14, n. 1, feb. 2026. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/7163>. Date accessed: 22 feb. 2026. doi: https://doi.org/10.18103/mra.v14i1.7163.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 14 No 1 (2026): Vol.14, Issue 1, January 2026
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med. 372:2018–28, 2015.
2. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:823–1833, 2016.
3. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-postive, advanced non-small-cell lung cancer (KEYNOTE -010): A randomised controlled trial. Lancet 387: 1540-1550, 2016.
4. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non–small-cell lung cancer. N Engl J Med. 2023;389(18):1672-1684 (Including Supplement and Protocol).
5. IMFINZI® (durvalumab) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
6. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable NSCLC: updated outcomes from the phase 3 AEGEAN trial. Presented at: IASLC 2024 World Conference on Lung Cancer; September 7-10, 2024; San Diego, CA. Abstract OA1
7. Cheng Y. et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med 2024; 391:1313-1327.
8. Herbst RS, Wu Yi-long, John T (2023) Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results from the Phase III Randomized ADAURA Trial. J Clin Oncol 41(10): 1830-1840.
9. Lv C, Fang W, Wu N, Jiao W, Xu S, et al. Osimertinib as Neoadjuvant Therapy for EGFR-Mutant Resectable Stage II-IIIB Lung Adenocarcinoma. Lung Cancer (2023), 178: 151-156.
10. Zhou C, Chen J Wu L, et al: Phase 3 study of ivonescimab (AK112) vs pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: Primary analysis of HARMONi-2. 2024 World Conference on Lung Cancer. Abstract PL02.04. Presented September 8, 2024.
11. Wang L, Luo Y, Ren S, et al: A phase 1b study of ivonescimab, a programmed cell death protein-1 and vascular endothelial growth factor bispecific antibody, as first- or second-line therapy for advanced or metastatic immune-therapy-naive NSCLC. J Thorac Oncol 19:465-475, 2024.
12. 12-Guirgis, HM. Cost Comparison of The Bispecific Ivonescimab, Immune Check Point Inhibitors and Target Therapy in advanced/metastatic Lung Cancer. J Cancer Sci Treatment, 7(1): 228-231.
13. .Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: A framework to assess the value of cancer treatment options. J Clin Oncol. June 22, 2015.
14. Cherny NI, Sullivan R, Dafni U, et al. A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. The European Society for Medical Oncology: magnitude of clinical benefit scale (ESM-MCBS): Oxford University Press; 2015.
15. 15-Guirgis. HM. Costs of Target Therapy and Proportionality to Number of Purchases: Propose Using Maintenance Dose and Limited Duration. ESMED 2024. Doi https://doi.org/10.18103/mra.v 12i1.4959. ISSN:2375-1924